[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100583534":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":10,"centralContacts":27,"locations":37,"responsibleParty":71,"collaborators":10,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":10,"enrollmentInfo":83,"targetDuration":86,"studyType":87,"phases":10,"briefSummary":88,"conditions":89,"keywords":93,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"University of Kansas Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Endometrial cancer survivors with weight management",null,"Survivors of low-risk early-stage endometrial cancer up to 36 months post primary treatment with body mass index (BMI) ≥30 kg\u002Fm2",[13,14],"Behavioral: Weight loss with pharmacotherapy","Behavioral: Weight loss without pharmacotherapy",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"BEHAVIORAL","Weight loss with pharmacotherapy","Patients will meet with a weight management specialist and discuss their options for weight loss including medications (GLP-1 agonist, naltrexone\u002Fbupropion, orlistat, or phentermine\u002Ftopiramate) or bariatric surgery.",[9],[22],"Weight loss medications",{"type":17,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"Weight loss without pharmacotherapy","Participants not on medications will have their weight recorded at subsequent cancer surveillance or other routine medical visits",[9],[28,33],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Principal Investigator","CONTACT","913-588-0885","mjavellana@kumc.edu",{"name":34,"role":30,"phone":35,"phoneExt":10,"email":36},"Co-investigator","913-588-1593","yabedin@kumc.edu",[38],{"facility":5,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Kansas City","Kansas","66160","United States","US",{"type":46,"coordinates":47},"Point",[48,49],-94.62746,39.11417,{"lat":49,"lon":48},[52,53,56,59,61,63,65,67,69],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},{"name":54,"role":55,"phone":10,"phoneExt":10,"email":10},"Melissa Javellana, MD","PRINCIPAL_INVESTIGATOR",{"name":57,"role":58,"phone":10,"phoneExt":10,"email":10},"Yasmin Abedin, MD","SUB_INVESTIGATOR",{"name":60,"role":58,"phone":10,"phoneExt":10,"email":10},"Ian Cook, MD",{"name":62,"role":58,"phone":10,"phoneExt":10,"email":10},"Johanna Finkle, MD",{"name":64,"role":58,"phone":10,"phoneExt":10,"email":10},"Andrea Jewell, MD",{"name":66,"role":58,"phone":10,"phoneExt":10,"email":10},"Lori Spoozak, MD",{"name":68,"role":58,"phone":10,"phoneExt":10,"email":10},"Rana Aliani, MD",{"name":70,"role":58,"phone":10,"phoneExt":10,"email":10},"Thomas Chavez, MD",{"type":55,"investigatorFullName":72,"investigatorTitle":29,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Melissa Javellana","100583534","weight-loss-management-in-endometrial-cancer-survivors-100583534",false,"NCT06877572","Weight Loss Management in Endometrial Cancer Survivors","Enacting Active Survivorship: Implementation of Weight Management Strategies in Endometrial Cancer Survivors","ECS Weight","Inclusion Criteria:\n\n* ≥18 years old\n* ECOG 0-2\n* BMI ≥ 30kg\u002Fm2\n* Completed surgical staging with no evidence of residual disease\n* Endometrioid endometrial adenocarcinoma, p53 wild type\n* Stage 1\n* Undergoing active surveillance +\u002F- brachytherapy\n\nExclusion Criteria:\n\n* Unable to participate in behavior weight loss\n* Stroke, heart attack, end stage liver disease, or end stage kidney disease during the last 6 months.\n* Currently on a GLP-1 agonist\n* Currently on insulin","FEMALE","18 Years",{"count":84,"type":85},50,"ESTIMATED","1 Year","OBSERVATIONAL","This study is being done to understand how oncologists can engage a multidisciplinary team to help endometrial cancer survivors with obesity to engage in a weight management program and potentially start a weight loss medication. Obesity often impacts the future health and longevity of early-stage endometrial cancer survivors more than their cancer diagnosis.\n\nPatients will be referred to the KUMC OB\u002FGyn weight management clinic to discuss weight management options.\n\n* If patients decide to use medications for weight loss, then the study will collect data from their chart that is recorded as part of routine monitoring for patients on weight loss medications.\n* If patients decide not to use any medications, the study will monitor physical exam and lab data collected as part of their routine medical care.\n\nThe study will also try to understand reasons why patients did or did not start using a weight loss medication.",[90,91,92],"Endometrial Cancer Survivors","Weight Management","Early Stage Endometrial Cancer",[94,90,91,95,96,97,98],"Endometrial Cancer","GLP-1 agonist","naltrexone\u002Fbupropion","orlistat","phentermine\u002Ftopiramate","2025-10-23",{"date":101,"type":102},"2025-10-27","ACTUAL",{"date":104,"type":102},"2025-03-25",{"date":106,"type":85},"2030-10",{"name":5,"class":6},1]